Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Rapid Administration Pilot for Infusing Dinutuximab [Phase 1]
This clinical trial update reports a Phase 1 pilot study evaluating rapid administration of dinutuximab for neuroblastoma, currently active …
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) [Phase 1]
Phase 1 SABRE trial evaluating selective antigen-specific T cells and CAR T cells in relapsed/refractory embryonal tumors, including rhabdom…
-
CLINICAL_TRIALS research · 2026-01-26Clinical Trial Update: Biomarkers of Resiliency In Childhood Cancer Surgery
Clinical trial update from Mayo Clinic on biomarkers of resiliency in pediatric cancer surgery, currently recruiting.
-
CLINICAL_TRIALS other · 2026-01-22Clinical Trial Update: B7-H3.CD28Z.CART in Solid Tumors [Phase 1]
Clinical trial update for the B7-H3.CD28Z.CART therapy in pediatric solid tumors and neuroblastoma. The study is currently not yet recruitin…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma [Phase 2]
Phase 2 trial evaluating irinotecan hydrochloride, temozolomide, and dinutuximab with or without eflornithine for relapsed or refractory neu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma [Phase 1]
Phase 1 trial sponsored by the National Cancer Institute evaluated the combination of magrolimab and dinutuximab in pediatric patients with …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Neuroblastoma Maintenance Therapy Trial [Phase 2]
This document announces a Phase 2 neuroblastoma maintenance therapy trial that is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Multi-Arm, Platform Trial For Relapsed Neuroblastoma [Phase 1, Phase 2]
A multi-arm platform trial for relapsed neuroblastoma spanning Phase 1 and Phase 2 is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
Clinical trial update describing a long-term follow-up study of late effects after treatment in patients with high-risk neuroblastoma; the s…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients [Phase 1]
Phase 1 trial assessing EBV-specific cytotoxic T cells engineered to express a GD-2 chimeric antigen receptor in neuroblastoma patients has …
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma [Phase 1, Phase 2]
Clinical trial update describing a phase 1/phase 2 study of Hu3F8 in combination with GM-CSF for relapsed/refractory high-risk neuroblastoma…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children [Phase 2]
A Phase II clinical trial is evaluating chidamide, dinutuximab beta, irinotecan, and temozolomide for refractory/relapsed neuroblastoma in c…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Phase II Study of Proton Radiation Therapy for Neuroblastoma [NA]
A Phase II clinical trial is evaluating proton radiation therapy for neuroblastoma and related ganglioneuroblastoma, currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma [Phase 1]
Phase 1 clinical trial update on GPC2 CAR T cells for relapsed/refractory neuroblastoma and metastatic retinoblastoma; currently recruiting.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma [Phase 1]
A Phase 1 clinical trial evaluating PHOX2B PC-CAR T cells for relapsed or refractory neuroblastoma, with recruitment ongoing.
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating hALK.CAR T cells in children with relapsed or refractory high-risk neuroblastoma; the study is current…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma [Phase 1]
Phase 1 clinical trial evaluating allogeneic expanded gamma delta T cells combined with GD2-targeted chemoimmunotherapy in relapsed/refracto…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma [Phase 3]
A Phase 3 clinical trial update investigates response and biology-based risk-factor guided therapy for younger patients with non-high risk n…
-
CLINICAL_TRIALS trial_result · 2025-12-18Clinical Trial Update: MIBG for Refractory Neuroblastoma and Pheochromocytoma [NA]
The clinical trial evaluating MIBG for relapsed neuroblastoma and metastatic pheochromocytoma has completed.
-
CLINICAL_TRIALS research · 2025-12-12Clinical Trial Update: Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）
Clinical trial update indicating the status of a study evaluating eflornithine after immunotherapy for high-risk neuroblastoma; the trial is…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study [NA]
A pilot PET imaging trial using the 124I-labeled humanized antibody 3F8 to visualize solid tumors, including melanoma, neuroblastoma, and sa…
-
CLINICAL_TRIALS trial_result · 2025-12-03Clinical Trial Update: Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma [NA]
Clinical trial update indicates hetrombopag is being studied to promote platelet engraftment after autologous hematopoietic stem cell transp…
-
CLINICAL_TRIALS other · 2025-12-03Clinical Trial Update: NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab [Phase 2]
Phase 2 randomized neuroblastoma trial evaluating metaiodobenzylguanidine (MIBG) with vorinostat and dinutuximab. The study is not yet recru…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma [EARLY_Phase 1]
This report updates an early-phase 1 trial using 18F-fluorodopamine PET imaging in neuroblastoma and pheochromocytoma. The study is currentl…
-
EMA approval · 2025-11-26EMA Authorised: Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) (Dinutuximab beta) — Recordati Netherlands B.V.
The EMA authorised Qarziba (dinutuximab beta) for neuroblastoma, with orphan medicine status, under Recordati Netherlands B.V. as the market…